Relapsed/refractory multiple myeloma after prior therapies is one of the principal clinical settings represented for Pomalidomide. Cereblon-binding immunomodulatory drug that promotes degradation of transcription factors and alters immune signaling. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. The medicine is classified as Targeted Therapy; Immunomodulatory Agent and belongs to the IMiD family. In practice, its use extends to Relapsed/refractory multiple myeloma after prior therapies. The tumor types represented here include Multiple Myeloma. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Treatment may be organized around Pomalidomide + dexamethasone; pomalidomide + daratumumab + dexamethasone; other myeloma combinations. These combinations show how the agent is incorporated into disease-specific treatment rather than used as a stand-alone concept across all cancers. The indication should be interpreted together with disease stage, histology, previous treatment, and any molecular or receptor requirement stated in the record. The mechanism also helps distinguish this medicine from other agents used for similar tumors. Current clinical use can vary by jurisdiction and by changes in regulatory labeling or guideline recommendations. This entry is intended as a reference summary, not as individualized prescribing advice.